All splice variants
PIK3CD-L and -S CTGAGCTCTCAGAAGACC GCTCGCGGTTGATTCCAA PIK3CD-L GGTACTCCGTTCAGACACCA GCTCGCGGTTGATTCCAA PIK3CD-S TGGACCTGAGGGAGGCCCT GCTCGCGGTTGATTCCAA
FGFR3-L and -S AAGGGTAACCTGCGGGAGTT AGGTCGTGTGTGCAGTTGG

TSC2-L and -S AGGTTGCGCAGTTAGCAGTT GGTGCTTTCAGCAAAACCAT
ITGA4-L and -S TTTTGTGCCCATGAAAATTG TCAAGTTGTACCACGCCAGA
MET-L and -S TACCACTCCTTCCCTGCAAC TTTTCCAAGGACGGTTGAAG
NF-L and -S AGGTTGCGCAGTTAGCAGTT GGTGCTTTCAGCAAAACCAT
BAK1-L and -S ATGGCTTCGGGGCAAGGC TCATAGCGTCGGTTGATGTC
RASGRP2-a and -b
TGGAGCACATCGAGAAGATG AGCGCAGGAAATAGGAAACC CAGATCATCCGTGGGAACTT RASGRP2-a ATGGTTTCCTATTTCCTGCG TGTGACTCCTAGGGGCTGAGT RASGRP2-b ATGGTTTCCTATTTCCTGCG TTCTGGTCGAGGTCCCCAAA ATM-L and -S GCTACAGATTGCAACCCAATT ACAGTTGCTCAAGCAACGTGT GSK3A ACAGGAGTATGCCAGTGTCCA GGTGTAATCAGTGGCTCCAAA EPHA1 AGGGCATAGCATCTGGCATGA AGAATCAGAAGCGTGGAGTGC EIF1AX GTACTGGAGAGGGGAGAGCA TGAAGCTGAGACAAGCAGGA PPA1 GGCTGTTGTGGTGACAATGA TGACTTTCCAGTCGGTTTCC Supplementary* FGFR3 (S/L) TSC2 (S/L) ITGA4 (L/S) MET (L/S) NF1 (L/S) BAK1 (L/S)RASGRP2
-S, TSC2-S, ITGA4-L, MET-L, NF1-L, BAK1-L and RASGRP2-b; and plots for the EA-specific/-enriched variants FGFR3-L, TSC2-L, ITGA4-S, MET-S, NF1-S, BAK1-S and RASGRP2-a. EIF1AX
and PPA1 transcripts served as internal normalization controls. * P < 0.05 using Student t-test. K46  K210  S315  S312  S406  S411  Y484  Y485  S520  Y524  T935  Y936  T935   p85 binding  C2  Catalytic  Helical   K46  K210  S315  S312  S406  S411  Y484  Y485  S520  Y524  T935  Y936  T935   K46  K210  S406  S411  Y484  Y485  S520  Y524  T935  Y936  T935   K46  K210  S406  S411  Y484  Y485  S520  Y524  T935  Y936  T935   K46  K210  S315  S312  S406  S411  T935  Y936 Proliferation was assessed using a BrdU labeling assay. Data presented as the mean ± SEM of n=3-6 independent experiments for each treatment group. *P < 0.05 by ANOVA with Dunnett's post-hoc test.
RAS binding
Supplementary Fig. 8 . Knockdown of p85α increases invasive activity of EA PCa cell lines. Invasion was assessed using Matrigel assay following siRNA-mediated knockdown of p85a (PIK3R1). SiRNA-SMART pool for targeting PIK3R1 was purchased from Dharmacon (Lafayette, CO). Data presented as the mean ± SEM of n=3-4 independent experiments for each treatment group. *P < 0.05 by ANOVA with Dunnett's post-hoc test. siNS, Nonsense siRNA control.
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High S/L ratio Low S/L ratio Supplementary Fig. 9 . Survival plots for breast, colon and prostate cancer patients with high and low PIK3CD-S/PIK3CD-L expression ratios. RNA-Seq and disease free survival data for breast (n = 1,068 patients), colon (n = 277 patients) and prostate cancers (n = 494 patients) were obtained from The Cancer Genome Atlas (TCGA) (https://tcga-data.nci.nih.gov/tcga/). P-values for survival curves were determined by the log-rank test. 
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